Mandate

Vinge advises Impilo on the establishment of a continuation fund

November 15, 2024

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.

Impilo is a Nordic investment company specializing in investments within the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo holds a highly diversified portfolio of healthcare investments and manages approximately EUR 1 billion in capital, from leading Nordic and international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist and Viktoria Wnuk.

Related

Vinge has advised Stenhus Fastigheter i Norden AB in connection with their uplisting to Nasdaq Stockholm

Vinge has advised Stenhus Fastigheter i Norden AB (publ) (“Stenhus Fastigheter” or the “Company”) in connection with the Company's uplisting to Nasdaq Stockholm. The first day of trading on Nasdaq Stockholm was 18 December 2024.
December 20, 2024

Vinge advised Platzer on its sale of building rights in Södra Änggården to the property developer Bonava

The transaction is being carried out through a company acquisition at an underlying property value of SEK 186 million.
December 20, 2024

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest and land in Latvia

Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of 100% of the shares in the two Latvian companies SIA "Latvijas Mežu Aģentūra" and SIA "Vadakstes Meži" (the “Companies") from Skogsfond Baltikum AB (publ). The Companies own a total of 8,080 hectares of forest and land in Latvia.
December 16, 2024